EUVIMEDEUVIMED entdecken
Crossref

Immunophenotypic spectrum and mutational landscape of EBV ‐positive inflammatory follicular dendritic cell sarcoma

Jian-Chao Wang iD, Chen Wang iD, Fang-Fang Chen, Wen-Fang Zhang, Zi-Qing Yu, Xiao-Jiang Wang, Shu-Lin Li, Mu-Sheng Chen, Li-Hua Zhong, Li-Yan Lin, Yan-Ping Chen, Xin Chen und 2 weitere

Histopathology · 2026

DOI: 10.1111/his.70097 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2026. Verfasst von Jian-Chao Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Dendritic Cell Sarcoma, Follicular, Epstein-Barr Virus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the Scientific Research Foundation of Fujian Cancer Hospital (Grant number: 2022YNG08), the Joint Funds for the Innovation of Science and Technology, Fujian Province (Grant number: 2021Y9215).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Epstein–Barr virus (EBV)‐positive inflammatory follicular dendritic cell sarcoma (EBV+ IFDCS) is a rare, indolent malignant neoplasm. Due to its rarity, a comprehensive assessment of its immunophenotypic spectrum and molecular analysis is still lacking. This study aimed to characterize the immunophenotypic and genetic alterations of EBV+ IFDCS to improve understanding of its cell of origin and molecular pathogenesis and to identify potential therapeutic targets. Methods and results Immunohistochemical staining for a panel of follicular dendritic cell (FDC) and fibroblastic reticular cell (FRC) lineage markers, along with targeted next‐generation sequencing, was performed. Nineteen cases of EBV+ IFDCS were classified into four immunophenotypes: nine FDC, two FRC, three biphasic and five null phenotypes. Morphologically, cases with a null phenotype more frequently exhibited a lymphoma‐like growth pattern (4/5, 80%) compared with those with a definite FDC and/or FRC phenotype (1/14, 7.1%, P = 0.006). Moreover, a scattered distribution of neoplastic cells was more commonly observed in null phenotype cases (4/5, 80%) than in FDC and/or FRC phenotype cases (3/14, 21.4%, P = 0.038). Targeted sequencing revealed somatic variants in chromatin modifier‐related genes in 60.0% (9/15), homologous recombination repair (HRR)‐related genes in 53.3% (8/15) and Hippo pathway‐related genes ( FAT2 and FAT1 ) in 26.7% (4/15) of cases.

Conclusions

These findings demonstrate the wide morphological and immunophenotypic spectrum of EBV+ IFDCS. Furthermore, variants in chromatin modifier and HRR‐related genes may participate in its pathogenesis, and PARP inhibition may represent a potential therapeutic strategy for patients with unresectable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic Cell Sarcoma, FollicularEpstein-Barr Virus InfectionsHumansFemaleImmunophenotypingMiddle AgedAdultMaleMutationAgedHerpesvirus 4, HumanImmunohistochemistryAged, 80 and over

Stichwörter der Autor:innen

EBV‐positive inflammatory follicular dendritic cell sarcomagenetic alterationhomologous recombination repairimmunophenotype

Autor:innen und Institutionen

  • Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Pathology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
  • Department of Pathology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
  • Department of Pathology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Pathology, Chongqing University Cancer Hospital, Chongqing, China.
  • Fujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fujian Cancer Hospital, Fuzhou, China.

ORCID-Profile: Jian-Chao Wang, Chen Wang, Gang Chen

Förderung

  • the Scientific Research Foundation of Fujian Cancer Hospital (Grant number: 2022YNG08)
  • the Joint Funds for the Innovation of Science and Technology, Fujian Province (Grant number: 2021Y9215)

Zitieren

APA

Wang, J. C., Wang, C., Chen, F. F., Zhang, W. F., Yu, Z. Q., Wang, X. J., Li, S. L., Chen, M. S., Zhong, L. H., Lin, L. Y., Chen, Y. P., Chen, X., Chen, L. H., & Chen, G. (2026). Immunophenotypic spectrum and mutational landscape of EBV ‐positive inflammatory follicular dendritic cell sarcoma. Histopathology. https://doi.org/10.1111/his.70097

Vancouver

Wang JC, Wang C, Chen FF, Zhang WF, Yu ZQ, Wang XJ, et al. Immunophenotypic spectrum and mutational landscape of EBV ‐positive inflammatory follicular dendritic cell sarcoma. Histopathology. 2026. doi:10.1111/his.70097

BibTeX
@article{Wang2026,
  author = {Wang, Jian-Chao and Wang, Chen and Chen, Fang-Fang and Zhang, Wen-Fang and Yu, Zi-Qing and Wang, Xiao-Jiang and Li, Shu-Lin and Chen, Mu-Sheng and Zhong, Li-Hua and Lin, Li-Yan and Chen, Yan-Ping and Chen, Xin and Chen, Li-Hong and Chen, Gang},
  title = {Immunophenotypic spectrum and mutational landscape of EBV ‐positive inflammatory follicular dendritic cell sarcoma},
  journal = {Histopathology},
  year = {2026},
  doi = {10.1111/his.70097}
}
Kostenlos starten →